Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.41 · Revenue $4.26M · 2 analysts
Est. EPS $-1.04 · Revenue $34.50M · 2 analysts
Est. EPS $-4.85 · Revenue $38.21M · 5 analysts
Est. EPS $-0.99 · Revenue $44.55M · 1 analysts
EPS $-0.86 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-177.0M | -58.4% | -49.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-153.5M | -83.4% | -0.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 194.3% | +129.3% | -1715.3% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 10.55x | +36.8% | -27.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $466.6M | +90.3% | +101.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.78 vs -3.85 | +1.9% | -1.44 vs -1.16 | -23.7% |
| Revenue Surprise | $0 vs $1.2M | -100.0% | $0 vs $3.9M | -100.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Common Stock | A | 20,000 | — |
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Performance Stock Units | A | 10,000 | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Common Stock | A | 80,000 | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Performance Stock Units | A | 120,000 | — |
| Aug 14, 2026 | Hahne Vicky | officer: Chief Financial Officer | Common Stock | A | 16,000 | — |
Operator: Good afternoon, ladies and gentlemen. Welcome to Security second Quarter 26 Financial Results Conference Call and Webcast. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. I would now like to turn the conference over to Jodi Sievers, corporate communications and investor relations at Celcuity. Please go ahead. Jodi Sievers: Thank you, Ludi, and good afternoon to everyone. Thank you for joining us today to read Celcuity's second quarter 26 financial results and business update. Earlier today, Cellcuity released financial results for the quarter ended 06/30/2026. The press release can be found on the Investors section of Celcuity's website Joining me on the call today are Brian F. Sullivan, Celcuity's Chief executive officer and cofounder Vicky Hahne, chief financial officer as well as Igor Gorbachevsky, chief medical officer; and Eldon C. Mayer, chief commercial officer, who will be available during Q&A. As we begin, I would like to remind listeners that our comments today will include some forward looking statements. These statements involve a number of risks and uncertainties which are outlined in today's press release and in our reports and filings with the SEC. Actual events and results may differ materially from those projected in the forward looking statements. Such forward looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. On this call, we will also refer to non GAAP financial measures. These non GAAP financial measures are used by management to make strategic decisions forecast future results, evaluate the company's current performance. Management believes the presentation of these non GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non GAAP financial measures to the GAAP measures in today's press release and with the And with that, I would like to turn the call over to Brian F. Sullivan, CEO of Cellcuity. Operator: Please go ahead, Brian. Brian F. Sullivan: Thank you, Jodi, and good afternoon, everyone. Thank you for joining our second quarter 26 operating and financial update conference call. Celcuity continues to make monumental progress. Advancing clinical development of gedatolisib for patients with HR positive, HER 2 negative advanced breast cancer. With the FDA approval of Revtopik, positive results from the PIK3CA mutant cohort of our pivotal VIKTORIA-1 study, and a preferred category 1 recommendation in the NCCN guidelines. We are well positioned to address a significant unmet need for the tens of thousands of patients each year by HR positive, HER 2 negative advanced …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | USD 945,218 | Male | 1962 | Active |
Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | USD 673,781 | — | 1962 | Active |
Vicky Hahne | Chief Financial Officer | USD 598,079 | Female | 1966 | Active |
Igor Gorbatchevsky | Chief Medical Officer | — | Male | — | Active |
Eldon C. Mayer | Chief Commercial Officer | — | Male | 1961 | Active |
Jodi Sievers | Head of Investor Relations & Corporate Communications | — | Female | — | Active |
Sheri Smith | Acting Head of Clinical Operations | — | Female | — | Active |
Brent Eilefson | General Counsel | — | Male | — | Active |
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy.
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,621 shares of the company's stock, valued at approximately $693,000. Several other hedge funds have also
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
